EBV

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
星期四, 四月 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Retrieved on: 
星期二, 三月 26, 2024
Fibromyalgia, DSM-IV codes, Epstein–Barr virus, WIPO, COVID-19, Patient, Conditional sentence, Orthostatic intolerance, System, Celecoxib, Anxiety, Medical statistics, EBV, MD, Fatigue, Treatment, Therapy, Patent, Pain, Valaciclovir, FDA, Pharmaceutical industry

ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that the World Intellectual Property Organization (WIPO) has published Virios’ global patent application titled “Valacyclovir and Celecoxib for the Treatment of Alzheimer’s and COVID-19”, which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.

Key Points: 
  • This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
  • An open-label, exploratory LC study sponsored by Virios demonstrated that treatment with the combination of valacyclovir and celecoxib resulted in clinical and statistically significant reductions in LC associated fatigue, orthostatic intolerance, pain and anxiety.
  • Previous estimates suggest that up to 10 million children in the US have also experienced LC.
  • There are no treatments approved by the FDA to treat the symptoms associated with LC, further highlighting the need for new treatments.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期五, 四月 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, EBV, Epstein–Barr virus, ATRA, Patient, Employment, Cancer, Compensated emancipation

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
  • This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Retrieved on: 
星期四, 三月 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, The Lancet, Research, Graft-versus-host disease, LD, ASH, International Society, Partnership, Central nervous system, ATRA, Epstein–Barr virus, Patient, Follicular lymphoma, CNS, Biomarker, PTLD, Cancer, Lymphoproliferative disorders, SLE, EBV, NHL, Lymphoma, Mantle cell lymphoma, Investment, ATM, Safety, Pharmacokinetics, Depreciation, File, Workforce, Cell, FDA, BLA, Lupus nephritis, CD19, Food, Autoimmune disease, Pharmaceutical industry

“We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • “This includes strong momentum for our lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkin’s lymphoma and lupus nephritis.
  • Subjects will receive lymphodepletion (LD) treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

EQS-News: Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Retrieved on: 
星期三, 三月 13, 2024
Cleveland Clinic, Research, Biotechnology, MD, Quality of life, Treatment, Hope, Multiple sclerosis, COVID-19, EBV, AFL, Fatigue, COVID, PMS, Patient, Clinical trial, Serum, Pharmaceutical industry

“Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.

Key Points: 
  • “Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • We believe that the data set provides biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Recent third-party data in post COVID patients identified EBV reactivation as a potential cause for fatigue in this patient group.
  • Fox, MD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

Retrieved on: 
星期四, 二月 29, 2024
SAN, FDA, Food, Stage 2, PTCL, Epstein–Barr virus, Valganciclovir, EBV, Therapy, Patient, Peripheral T-cell lymphoma, Pharmaceutical industry

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its lead development program, Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, has completed Stage 2 enrollment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort of the NAVAL-1 trial.

Key Points: 
  • “The completion of Stage 2 enrollment of the PTCL cohort in NAVAL-1 is a major milestone for the Nana-val clinical development program.
  • We would like to acknowledge the dedication of our study execution team and the commitment of our investigators for this achievement.
  • Present Stage 1 + Stage 2 data (n=21) from the R/R EBV+ PTCL cohort in patients treated with Nana-val in the third quarter of 2024.
  • Engage with the U.S. Food and Drug Administration (FDA) in mid-2024, to align on requirements for accelerated approval.

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Retrieved on: 
星期四, 二月 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Investigational New Drug, Woman, Autoimmune disease, Physician, FDA, Food, CD19, Epstein–Barr virus, Risk, Leukapheresis, Prevalence, Safety, Lupus, Kidney, ATRA, EBV, Disease, Patient, Lupus nephritis, SLE, IND, Tissue, Mortality, Cancer

We are eager to address the significant unmet need in lupus nephritis as we initiate our Phase 1 trial,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • We are eager to address the significant unmet need in lupus nephritis as we initiate our Phase 1 trial,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • “CAR T cells can naturally infiltrate deep into target tissues to mediate B-cell depletion and produce durable responses.
  • The ATA3219 IND submission included in vitro data reflecting the CD19 antigen-specific functional activity of ATA3219 and CAR-mediated activity against B cells from SLE patients.

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Retrieved on: 
星期三, 二月 28, 2024
Oncology, Health, Infectious Diseases, Genetics, Pharmaceutical, Biotechnology, PST, EST, ATRA, EBV, Conference, Epstein–Barr virus, Webcast, Patient, Cancer

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.
  • A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
  • An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Retrieved on: 
星期三, 二月 14, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Investigational New Drug, Woman, Immune system, Autoimmune disease, Physician, Food, Technical, CD19, Epstein–Barr virus, Risk, Prevalence, Lupus, Kidney, ATRA, EBV, Phenotype, Disease, Patient, Lupus nephritis, Survival, SLE, IND, Mortality, Cancer, Vaccine

“We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference.

Key Points: 
  • “We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference.
  • Treatment will be facilitated for patients and physicians in avoiding apheresis and lengthy patient-by-patient manufacturing as ATA3219 would be rapidly available as an off-the-shelf treatment from finished product inventory.
  • The ATA3219 IND submission includes robust in vitro data reflecting the CD19 antigen-specific functional activity of ATA3219 and CAR-mediated activity against B cells from SLE patients.
  • Despite recent advances in treatment strategies, the response rate using existing therapies remains low, with significant risk of long-term morbidity and mortality associated with refractory LN.

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Retrieved on: 
星期三, 一月 31, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Rituximab, Survival, European, EBV, Graft-versus-host disease, MHRA, The Lancet, Patient, FDA, EMA, SOT, Cytokine release syndrome, Society, ATRA, ASH, HCT, Cancer, BLA, Lymphoproliferative disorders, Epstein–Barr virus

22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).

Key Points: 
  • 22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).
  • The median duration of response was 23.0 months and the median overall survival was 18.4 months.
  • These interim data were previously presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
  • All this resonates perfectly with our purpose ‘every time we care for a single person, we make the whole world better,’” said Núria Perez-Cullell, Director of Medical Affairs, Patients & Consumers at Pierre Fabre Laboratories.